GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anti-Microbial Savior BioteQ Co Ltd (ROCO:6864) » Definitions » EV-to-EBIT

Anti-Microbialvior BioteQ Co (ROCO:6864) EV-to-EBIT : -11.54 (As of Jun. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Anti-Microbialvior BioteQ Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Anti-Microbialvior BioteQ Co's Enterprise Value is NT$655.16 Mil. Anti-Microbialvior BioteQ Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-56.75 Mil. Therefore, Anti-Microbialvior BioteQ Co's EV-to-EBIT for today is -11.54.

The historical rank and industry rank for Anti-Microbialvior BioteQ Co's EV-to-EBIT or its related term are showing as below:

ROCO:6864' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.72   Med: -13.6   Max: -9.39
Current: -11.54

During the past 6 years, the highest EV-to-EBIT of Anti-Microbialvior BioteQ Co was -9.39. The lowest was -31.72. And the median was -13.60.

ROCO:6864's EV-to-EBIT is ranked worse than
100% of 438 companies
in the Biotechnology industry
Industry Median: 8.76 vs ROCO:6864: -11.54

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Anti-Microbialvior BioteQ Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$552.96 Mil. Anti-Microbialvior BioteQ Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-56.75 Mil. Anti-Microbialvior BioteQ Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -10.26%.


Anti-Microbialvior BioteQ Co EV-to-EBIT Historical Data

The historical data trend for Anti-Microbialvior BioteQ Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anti-Microbialvior BioteQ Co EV-to-EBIT Chart

Anti-Microbialvior BioteQ Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - - -47.22 -16.06 -9.74

Anti-Microbialvior BioteQ Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only -47.22 - -16.06 - -9.74

Competitive Comparison of Anti-Microbialvior BioteQ Co's EV-to-EBIT

For the Biotechnology subindustry, Anti-Microbialvior BioteQ Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anti-Microbialvior BioteQ Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anti-Microbialvior BioteQ Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anti-Microbialvior BioteQ Co's EV-to-EBIT falls into.



Anti-Microbialvior BioteQ Co EV-to-EBIT Calculation

Anti-Microbialvior BioteQ Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=655.156/-56.749
=-11.54

Anti-Microbialvior BioteQ Co's current Enterprise Value is NT$655.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anti-Microbialvior BioteQ Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-56.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anti-Microbialvior BioteQ Co  (ROCO:6864) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Anti-Microbialvior BioteQ Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-56.749/552.95573825
=-10.26 %

Anti-Microbialvior BioteQ Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$552.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anti-Microbialvior BioteQ Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-56.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anti-Microbialvior BioteQ Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Anti-Microbialvior BioteQ Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Anti-Microbialvior BioteQ Co (ROCO:6864) Business Description

Traded in Other Exchanges
N/A
Address
Sec.1, Huandong Road, 1 Floor, No. 2, Ln. 31, Xinshi District, Tainan, TWN, 741
Anti-Microbial Savior BioteQ Co Ltd is engaged in drug research and development as well as development and technology patenting of medical fungi.

Anti-Microbialvior BioteQ Co (ROCO:6864) Headlines

No Headlines